RGX-181

N/A

Report date: 2024/09/02 13:21:27

Base Information

Drug NameRGX-181
Drug Alias NameRGX-181AAV9.hCLN2TTX-181
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transferenceTripeptidyl peptidase 1 replacements
TargetsTripeptidyl Peptidase 1
Therapy Area/IndicationsNeuronal ceroid lipofuscinosis type 2Neuronal Ceroid-Lipofuscinoses
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesRegenxbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesTern TherapeuticsRegenxbio Inc
Inactive CompaniesN/A
Active IndicationsNeuronal ceroid lipofuscinosis type 2
Inactive IndicationsNeuronal Ceroid-Lipofuscinoses

Other Information

ATC CodeN/A
Related LinksN/A